Bristol Myers Squibb (CELG-RI) Cash from Financing Activities (2009 - 2026)

Bristol Myers Squibb has disclosed Cash from Financing Activities across 18 years of filings, most recently posting -$1.6 billion for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 57.1% year-over-year to -$1.6 billion; the TTM figure through Mar 2026 stood at -$10.9 billion (down 3.85% YoY), while the FY2025 annual figure was -$10.3 billion, down 301.83% from the prior year.
• Cash from Financing Activities grew to -$1.6 billion in Q1 2026, from -$6.0 billion in the prior quarter.
• Over the last five years, Cash from Financing Activities for CELG-RI reached as high as $14.6 billion in Q1 2024 and fell as low as -$6.0 billion in Q4 2025.
• The 5-year median for Cash from Financing Activities is -$3.1 billion (2023), against an average of -$2.0 billion.
• The widest YoY moves for Cash from Financing Activities: up 580.13% in 2024, down 269.8% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at -$3.2 billion in 2022, then jumped by 129.79% to $967.0 million in 2023, then tumbled by 269.8% to -$1.6 billion in 2024, then plunged by 267.17% to -$6.0 billion in 2025, then jumped by 74.13% to -$1.6 billion in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$1.6 billion, -$6.0 billion, and -$1.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.